BHC
Bausch Health Companies Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum-inputs (vergelijkbare managers):
breedte van houders -5.9% ·
aandelenstroom -7.8% ·
netto nieuwe posities -6.2%
— formule
Brede distributie — dalende aandelen en minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | -5 | 75.64M | $382.99M | +3 | −7 |
| Q1 2026 | 85 | -6 | 79.75M | $438.97M | +2 | −9 |
| Q4 2025 | 92 | +1 | 89.74M | $627.51M | +2 | — |
| Q3 2025 | 19 | +1 | 25.30M | $166.30M | +2 | −2 |
| Q2 2025 | 16 | -1 | 54.52M | $364.89M | — | −1 |
| Q1 2025 | 15 | +1 | 47.24M | $307.27M | +2 | −1 |
| Q4 2024 | 14 | +1 | 50.10M | $405.72M | +1 | — |
| Q3 2024 | 13 | +1 | 47.82M | $391.50M | +2 | −1 |
| Q2 2024 | 12 | — | 55.66M | $388.80M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Icahn Capital ✦ | 34.72M | 0.0% | $231.24M | 2.9% | Held | 5 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passief) | 11.77M | — | $78.48M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passief) | 11.77M | — | $78.48M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | The Vanguard Group ✦ (passief) | 11.77M | — | $78.48M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | The Vanguard Group ✦ (passief) | 11.77M | — | $78.48M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | The Vanguard Group ✦ (passief) | 11.77M | — | $78.48M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Arrowstreet Capital ✦ | 1.76M | -59.3% | $11.74M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 8 | Oaktree Capital Management ✦ | 1.27M | 0.0% | $8.46M | 0.2% | Held | 5 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passief) | 840.42K | +11.2% | $7.26M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passief) | 840.42K | +11.2% | $7.26M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 11 | GAMCO Investors ✦ | 997.01K | -4.5% | $6.64M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 760.98K | -16.3% | $5.07M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Bridgewater Associates ✦ | 744.56K | -8.0% | $4.96M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 581.72K | +6.2% | $3.88M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 581.72K | +6.2% | $3.88M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 16 | Millennium Management ✦ | 556.19K | +30.6% | $3.70M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 193.63K | -20.4% | $1.29M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Marshall Wace ✦ | 112.00K | -84.6% | $745,920 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Marshall Wace ✦ | 112.00K | -84.6% | $745,920 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | BlackRock ✦ (passief) | 99.55K | — | $662,996 | 0.0% | n/c | 1 | SEC ↗ |
| 21 | BlackRock ✦ (passief) | 99.55K | — | $662,996 | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 75.46K | -26.3% | $502,550 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 23 | Citadel Advisors ✦ | 21.82K | -98.3% | $145,321 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 24 | Citadel Advisors ✦ | 21.82K | -98.3% | $145,321 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 25 | Norges Bank ✦ (passief) | 17.52K | 0.0% | $116,657 | 0.0% | Held | 5 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Point72 Asset Management | $541,500 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 224 houders, 232.19M aandelen, $1.23B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 36.83K aand · $258,894
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie